The more rapid growth of untreated MC38 tumors in GEFH1−/− animals in the early phase of tumor immune control, i.e., when the tumor burden is low, indicates that the GEF-H1 axis may be involved in the early events that control tumor immunity, DC activation, and tumor antigen presentation. The gene discussed is ARHGEF2; the disease is neoplasm.